What's Hot
View all perspectives
Mike Putman EBRheum
3 years 1 month ago
Important late breaker @TerrierBen, DBRCT of RTX vs GC (FFS=0) or CYC (FFS>0) for EGPA
RTX not superior to CYC (64% RTX vs 60% CYC BVAS remission d180, p = 0.745); similar in subgroups
Feel like this lends support to (~surprising) ACR/VF recs for EGPA?
#ACR21 #ACRAmbassador https://t.co/gpsPtXF6pj
Eric Dein ericdeinmd
3 years 1 month ago
#ACR21 L19: TitAIN: Secukinumab for GCA
⭐️Phase 2 study with n=52
⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8%
⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g)
- Looking forward to larger study
@Rheumnow
https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg
TheDaoIndex KDAO2011
3 years 1 month ago
IL-17i for GCA? TitAIN study met all endpoints!
phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB
👉effective sustained remission
👉longer time to GCA flare
👉lower dose of steroids by week 52
👉no increase in AEs
#ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Increased age at PSO diagnosis was significantly associated with shorter transition time between PSO and PsA diagnoses. No other variables, including BSA, were associated with time to transition @RheumNow #ACR21 Abst#1798 https://t.co/fLPBHKAMAc
Dr. Rachel Tate uptoTate
3 years 1 month ago
Composite MACE outcomes no different among PsA pts treated w/ biologics and DMARDs. Abs 1833 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/TxyE4Uqttq https://t.co/Eykxwmcc44
David Liew drdavidliew
3 years 1 month ago
Secukinumab in GCA, phase 2 (TitAIN):
I can't deny this is promising, but phase 2 needs to be
interesting both arms did worse than equivalents in GiACTA, TCZ phase 2 (?looser flare def)
@drpnash: "Bring on the phase 3 trials"
(recruitment started👀)
#ACR21 ABSTL19 @RheumNow https://t.co/25OAL9BqIZ
Eric Dein ericdeinmd
3 years 1 month ago
#ACR21 L20- Anti-IFN Ab Emapalumab for MAS/sJIA
⭐️⬆️IFN in models of HLH/MAS, neutralization may be helpful
⭐️Pilot study in 14 pts w inadequate response to high-dose IV GC
⭐️Ok to continue IL1i
▶️13/14 pts remission
▶️ SAEs: 1 CMV reactivation
https://t.co/cuM9LcEr4u @RheumNow https://t.co/USYGNtq4eC
Bella Mehta bella_mehta
3 years 1 month ago
I am still obsessed with the name MAGIC syndrome -mouth and genital ulcers with inflamed cartilage!!
14% of patients with relapsing polychondritis have this! They also have features of aortitis, Raynaud's phenomenon and anticollagen II antibodies @rheumnow #ACR21 abt#1876 https://t.co/UlQUZlBPfx
Bella Mehta bella_mehta
3 years 1 month ago
Having an auto-inflammatory disease specialist available via telemedicine/video for near home providers for pts. Well received by primary care, pediatricians and internal medicine physicians. Will improve the care of auto inflammatory patients! #ACR21 @rheumnow #abt1062
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated MAS, Emapalumab (anti-IFNγ) induced remission in all pts with median 25 days, neutralised CXCL9 and allowed rapid steroid reduction @RheumNow #ACRBest https://t.co/7tnaS5tPJ0 https://t.co/G1IoFxLQoX
Janet Pope Janetbirdope
3 years 1 month ago
What if a celebrity had #Scleroderma? Would that ⬆️attention & funding for this rare disease? See what Big Bird says @RheumNow #ACR21 ?affected #PetsofACR @RheumNow @scleroderma @SclerodermaCAN audio-13.m4a
Eric Dein ericdeinmd
3 years 1 month ago
#ACR21 L21. REOVAS: RTX for EGPA
⭐️CYC traditionally preferred for 5-factor score>0
▶️Remission rates and relapse-free survival comparable bw RTX and conventional. RTX not superior for induction
▶️No diff in ANCA+/-, naive v relapse, FFS
https://t.co/cuM9LcEr4u @Rheumnow
Janet Pope Janetbirdope
3 years 1 month ago
#Rituximab NOT different from conventional Rx in #eGPA #churgstrauss abst#L21 v small study, 60% ANCA neg #ACR21 @RheumNow https://t.co/tO1vAF18y9
Dr. John Cush RheumNow
3 years 1 month ago
Miss anything from Day 1? We are sharing the best #ACR21 abstracts from Day 1.
https://t.co/YZ3jwW0Abu https://t.co/gvWCrIbWuG
Dr. John Cush RheumNow
3 years 1 month ago
Emapalumab (IFNg inhibitor) Effective in severe MAS (Ferritin 25K, failed anakinra, GC)- 14 pts (2-25 yrs; 4/14 sJIA)-13/14 remission, w rapid drops in CXCL9, Ferritin, ALT, DDimers & GC dose #ACR21 ABst LB20 https://t.co/05oW5C8Waf https://t.co/ecEkt3MY83
Poster Hall